A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland

A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland

Abstract Background New vaccines with broader protection against SARS-CoV-2 are needed to reduce the risk of immune escape and provide broad and long-lasting cellular immunity. The objectives of the naNO-COVID trial were to evaluate the safety and immunogenicity of a CD8 + T cell, gold nanoparticle-...

Full description

Saved in:
Bibliographic Details
Main Authors: Juliette Besson, Régine Audran, Maxime Karlen, Alix Miauton, Hélène Maby-El Hajjami, Loane Warpelin-Decrausaz, Loredana Sene, Sylvain Schaufelberger, Vincent Faivre, Mohamed Faouzi, Mary-Anne Hartley, François Spertini, Blaise Genton
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
SARS-CoV-2
Vaccine
Nanoparticle
Cellular
Immunity
Online Access:https://doi.org/10.1186/s12879-025-10844-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background New vaccines with broader protection against SARS-CoV-2 are needed to reduce the risk of immune escape and provide broad and long-lasting cellular immunity. The objectives of the naNO-COVID trial were to evaluate the safety and immunogenicity of a CD8 + T cell, gold nanoparticle-based, peptide COVID-19 vaccine. Methods A randomized, double-blind, vehicle-controlled, phase 1 trial in healthy adults to receive PepGNP-Covid19 or Vehicle-GNP, followed over 180 days, using a dose-escalation strategy. Results Twenty participants received PepGNP-Covid19 (low dose [LD] or high dose [HD], n = 10 each) and six Vehicle-GNP (LD or HD, n = 3 each). Vaccinations were safe. No serious adverse events were reported. Most of the adverse events were mild, two adverse events of special interest related to the product (fever and fatigue). Reactogenicity was similar overall between vaccine, comparator, and doses. Virus-specific humoral responses in LD PepGNP-Covid19 and Vehicle-GNP groups coincided with SARS-CoV-2 infections. PepGNP-Covid19 vaccination induced the modulation of Covid19-specific CD137 + CD69 + CD8 + , and an increase at day 35 particularly in central and effector memory T cells in LD group, and in late effector memory cells in HD group. Conclusions The favourable safety profile and cellular responses observed support further development of PepGNP-Covid19. Trial registration ClinicalTrials.gov, NCT05113862, approved 09.11.2021.
ISSN:1471-2334

Similar Items